文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

GeneXpert MTB/XDR能否实现扩大近患者结核药物敏感性检测的承诺?

Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?
PubMed 文献 · Lancet Infect Dis · 2022-02-25

本文探讨Xpert MTB/XDR检测在结核病耐药诊断中的优势与局限,指出该检测可检出异烟肼、乙硫异烟胺、氟喹诺酮类和二线注射剂耐药,适用于确诊肺结核患者,但WHO已下调二线注射剂在耐药结核治疗中的地位并修订耐药结核病例定义,可能削弱该检测的实际影响。

要点

  • Xpert MTB/XDR可检测异烟肼、乙硫异烟胺、氟喹诺酮类和二线注射剂耐药,适用于确诊肺结核患者。
  • WHO已下调二线注射剂在耐药结核治疗中的作用,并修订耐药结核病例定义以纳入新药耐药。
  • 该检测对扩大近患者耐药检测的预期影响可能因上述政策变化而低于预期。

核心结论

  • Xpert MTB/XDR检测在扩大耐药结核诊断可及性方面有前景,但WHO政策变化可能使其实际影响低于预期。

研究设计与样本

  • 本文为个人观点(Personal View)文章,探讨Xpert MTB/XDR检测在耐药结核诊断中的优势与局限、对药物选择的指导能力及在实验室诊断流程中的最佳定位。

主要发现

  • Xpert MTB/XDR可检测异烟肼、乙硫异烟胺、氟喹诺酮类和二线注射剂耐药,适用于确诊肺结核患者。
  • WHO已下调二线注射剂在耐药结核治疗中的地位,并修订耐药结核病例定义以纳入新药耐药。
  • 上述变化可能使该版本Xpert MTB/XDR检测卡的实际影响低于预期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early diagnosis, including universal drug-susceptibility testing for all patients with tuberculosis, remains a key priority for tuberculosis elimination by 2035. The drug-resistant tuberculosis care cascade remains persistently challenged by substantial gaps in timely diagnosis and treatment of drug-resistant tuberculosis. Current diagnostics for drug-resistant tuberculosis are limited with respect to accuracy, time to results, affordability, suitability for resource-poor endemic settings, and accessibility for use at the point of care. WHO endorsement of the novel Xpert MTB/XDR assay holds notable promise for expanding access to testing and rapid diagnosis of tuberculosis drug resistance. The Xpert MTB/XDR assay detects resistance to isoniazid, ethionamide, fluoroquinolones, and second-line injectables, and is indicated for testing in patients with confirmed pulmonary tuberculosis. However, this iteration of the Xpert MTB/XDR cartridge might have less of an effect than expected, as WHO has since downgraded the role of second-line injectable agents in treating drug-resistant tuberculosis, and has revised case definitions of drug-resistant tuberculosis to incorporate resistance to new drugs. This Personal View explores the strengths and limitations of the Xpert MTB/XDR assay in the detection of drug resistance, the assay's ability to inform appropriate drug-resistant tuberculosis drug selection, and the optimal placement of the Xpert XDR assay in the laboratory diagnostic workflow.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Naidoo K, Dookie N. Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? Lancet Infect Dis. 2022. PMID: 35227392. doi:10.1016/S1473-3099(21)00613-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。